Speakers

Panos Kanavos LSE Summit Director

Panos Kanavos is Associate Professor in International Health Policy and Deputy Director at LSE Health. He is also Programme Director of the Medical Technology Research Group (MTRG) at LSE Health, concentrating on interdisciplinary and comparative policy research on medical technologies. In addition to his work at LSE, Panos is Visiting Professor at the University of Basel, Switzerland. He also has a Visiting Appointment with the London School of Hygiene and Tropical Medicine.

Panos has previously acted as an advisor to a number of international governmental and nongovernmental organisations, including the European Commission and the World Health Organization. Comparative health policy and healthcare reform, pharmaceutical economics and socio-economic determinants of health are some of his many research interests.

Aris Angelis    LSE Summit Scientific Committee

Aris Angelis is a Research Officer at the Medical Technology Research Group, LSE Health, and a PhD candidate at the Department of Social Policy. His research interests include pharmaceutical economics, pricing and reimbursement policies of new medicines, health technology assessment and market access to innovative biomedical technologies. Aris’ PhD investigates the development of a methodological framework based on Multiple Criteria Decision Analysis (MCDA) for assessing the value of new medical technologies in the context of HTA, to inform resource allocation decisions and incentivise socially desirable R&D investments. Past work experience includes intern roles at Novartis and the Greek National Organization for Medicines. He holds an MSc in International Health Policy - Health Economics from LSE, an MSc in Biopharmacy from King’s College London and a BSc in Biochemistry from Imperial College London.

Karl Arnberg

Karl Arnberg has worked at the TLV (Sweden’s Dental and Pharmaceutical Benefits Agency) since 2004. He currently serves as Head of Unit. He has, among other things, been involved in TLV’s work with the further development of value-based pricing in Sweden, in which early access and real world data are important elements. He holds a Bachelor of Science and Economics from Lund University, Sweden.

Hala Audi

Hala Audi is the Head of the Review on AMR, on secondment from HM Treasury. Before joining the UK civil service, Hala was an international arbitration lawyer at Skadden, Arps, Slate, Meagher & Flom LLP in New York and London, advising clients in a range of industries including energy, construction and financial services. Hala studied law in Paris and at Columbia University Law School and public administration at the Kennedy School of Government and LSE.

Hanne Bak-Pedersen

Hanne Bak-Pedersen (MSc Pharm) is Programme Manager for Health Technologies and Pharmaceutical, at the World Health Organization Regional Office for Europe.

Mary Baker

Dr Mary Baker, MBE, is Immediate Past President of the European Brain Council and President of their ‘Year of the Brain’ project. Mary is Past President of the European Federation of Neurological Associations, Consultant to the World Health Organisation (WHO), Chair of the Working Group on Parkinson’s Disease, a member of the Strategic Advisory Board of the Human Brain Project, and a member of the Commission’s CONNECT Advisory Forum. Academic appointments include Associate Membership of the Health Services Research Unit, University of Oxford and Visiting Fellow within the London School of Economics and Political Science (LSE) Health Centre.

An Honorary Doctorate from the University of Surrey was conferred upon Mary in 2003 and an Honorary Doctor of Science degree was awarded by Aston University in July 2013. In 2009 she received the prestigious British Neuroscience Association Award for Outstanding Contribution to British Neuroscience and for Public Service. In 2014, Mary received the Dana/EDAB Lifetime Achievement Award for Outreach on Behalf of Brain Research and in 2015, she received the ECNP Media Award and in recognition of her contribution to and support of pharmaceutical medicine, an Honorary Fellowship of the Faculty of Pharmaceutical Medicine. Mary graduated from the University of Leeds with a BA Hons in Sociology and Political Theory.

Angelica Carletto

Angelica Carletto is a health cconomist currently employed at the Italian Medicines Agency (AIFA). She is involved in HTA activities related to pharmaceutical pricing and reimbursement and her main area of interest covers cost-effectiveness and budget impact analysis of pharmaceutical products. She has taken part in the scientific work of HTA collaboration networks at European and national level (eg EUnetHTA). One of her past research projects investigated methods and criteria for evaluating and implementing managed entry agreements for pharmaceuticals in Italy.She holds an MSc in Health Economics from the University of York and an MSc in Health Technology Assessment from Università Cattolica del Sacro Cuore, Rome.

Guillaume Dedet 

Guillaume Dedet is a technical officer at the World Health Organization regional office for Europe, based in Copenhagen, Denmark. His main areas of interest cover health technology assessment and pharmaceutical pricing and reimbursement policies. Prior to joining WHO, he served as a senior medical advisor in the pharmaceuticals pricing and reimbursement department at the French Ministry of Health.

Guillaume is a public health physician trained in Paris academic hospital, with a significant academic background in statistics (Université Paris Sud) and health economics (LSE). 

Hans-Georg Eichler

Hans-Georg Eichler, MD, MSc, is the Senior Medical Officer at the European Medicines Agency  in London, United Kingdom, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. Prior to joining the European Medicines Agency, Dr Eichler was at the Medical University of Vienna in Austria for 15 years. He was vice-rector for Research and International Relations since 2003, and professor and chair of the Department of Clinical Pharmacology since 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association.

His industry experience includes time spent at Ciba-Geigy Research Labs, UK, and Outcomes Research at Merck & Co., in New Jersey. In 2011, Dr Eichler was the Robert E. Wilhelm fellow at the Massachusetts Institute of Technology’s Center for International Studies, participating in a joint research project under the MIT’s NEWDIGS initiative.

Alessandra Ferrario   LSE Summit Scientific Committee

Alessandra Ferrario is Programme Co-Director for the Summit and a Research Officer in pharmaceutical and health policy at LSE. Her research focuses on access to medicines and non-communicable diseases. One of her current research projects looks at improving budget impact and cost-effectiveness of pharmaceutical products through the introduction of managed entry and risk-sharing agreements. She is also studying the burden and management of diabetes, both from a health and economic perspective, as part of a multi-country study in low- and middle-income countries. As part of her work on access to medicines, Alessandra is working with the World Health Organization on issues around availability, affordability and quality of medicines in the Republic of Moldova.

She holds an MSc in Health Policy, Planning and Financing (LSE/LSHTM), MSc in Epidemiology (Swiss Tropical and Public Health Institute, University of Basel) and BSc in Molecular Biology (University of Basel).

Finn Børlum Kristensen 

Professor Kristensen has been Head of the Coordinating Secretariat of European Network for HTA, EUnetHTA (www.eunethta.eu), in the Danish Health and Medicines Authority, DHMA, Copenhagen, since 2006, Chairman of its Executive Committee since 2010 and Adjunct professor in health services research and HTA at University of Southern Denmark since 1999.

He is a primary care physician and medical specialist in Public Health., with a PhD in Epidemiology. He was head of the Danish Centre for HTA (DACEHTA) from its establishment in DHMA, 1997-2009, Chairman, International Network of Agencies for HTA (INAHTA) 2003-06, and Chairman, HTA Council, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from 2013. He was Chief Editor of three peer reviewed publication series from DACEHTA 1998-2009 and Editor of a Health Technology Assessment Handbook (English, translated), 2007.

Christine Leopold

Dr Leopold is a Post-Doctoral Research Fellow in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. She received an Erwin Schroedinger Stipend from the Austrian Science Fund as well as a Thomas O. Pyle Research Scholarship from Harvard Medical School. Her current research interest focuses on disparities in breast cancer treatment in younger commercially insured women in the US. In addition, the assessment of value of new cancer medicines from different stakeholder perspectives is of great interest to Dr Leopold. She recently performed a study of decision-makers’ opinions on sustainable ways of funding highly-effective and costly specialty medicines in the US, Canada, Australia, New Zealand and Europe.

Her main research interests include ethical considerations in pharmaceutical pricing and reimbursement, evidence-based decision-making in pharmaceutical policy from different stakeholders’ perspectives and the assessment of the impact of policies on affordability of and accessibility to medicines. Prior to joining the Department of Population Medicine at Harvard Medical School she co-led the Austrian Centre for Rare Disease as well as the European Network of public authorities of Pharmaceutical Pricing and Reimbursement Information (PPRI) at the Department of Health Economics at the Austrian Public Health Institute / WHO Collaborating Center for Pharmaceutical Pricing and Reimbursement Policies. She holds a doctorate in Pharmaceutical Policy from Utrecht University and a Master of Science degree from Bocconi University in Italy.

Nicola Magrini

Nicola Magrini has 20 years of experience in drug evaluation and pharma­ceutical policies, having worked for 15 years in a NHS Centre for drug information and guideline development (NHS CeVEAS – Centre for the evaluation of the effectiveness of Health care, Modena. Italy) then at the Regional Health care Agency in Bologna, Italy and at the WHO since 2014 as Secretary of the Expert Committee on the Selection and Use of Essential Medicines. He is a medical doctor with a specialty in Clinical Pharmacology and a founder member of the Italian Cochrane Centre.

He started his career in academia in drug information and pharmacoepidemiology in Italy. He was then involved at national and international levels in areas such as evidence appraisal and synthesis, independent drug information programs and drug utilisation, guideline development and implementation, clinical research ethics and informed consent.

He was the Director of the WHO Collaborating Centre for Evidence-Based Research Synthesis and Guideline Development from 2008 until 2014.

Since April 2014 he has been leading the WHO Essential Medicines List Secretariat for the comprehensive 2015 EML update (May 2015) and is a member of the WHO Research Ethics Review Committee (WHO ERC).

He is currently Secretary of the WHO Expert Committee on the Selection and Use of Essential Medicines.

Richard Mason

Richard is the head of Johnson & Johnson Innovation, London. He joins Johnson & Johnson Innovation from XO1 Limited, where he served as CEO until the company was acquired by Janssen in March 2015.

Prior to his role at XO1, Richard was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions. 

Richard also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT).

Richard trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals.

Giovanni Mariggi 

Prior to joining Medicxi Ventures, Giovanni was a Principal with Index Ventures, having joined the firm in 2012. Before that he was at Cancer Research UK's London Research Institute (LRI; now the Crick Institute). At the LRI he conducted research focused on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects to biopharmaceutical companies in the oncology field. Giovanni currently sits on the board of directors of Gadeta, AbTco and Encare. He obtained a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.

Gordon McVie

Professor McVie is widely regarded as a leading international authority in the research and treatment of cancer. Having qualified in the 1960s in science and medicine at Edinburgh University, he was appointed Foundation Senior Lecturer at the Cancer Research Campaign oncology unit at the University of Glasgow in 1975. He trained in the US, and spent sabbaticals in Paris, Sydney and Amsterdam.He is currently Senior Consultant to the European Institute of Oncology, Milan, and is founding editor of ecancer.org, the first free open access cancer journal accepted by PubMed. He is visiting professor at the Universities of Milan, Glasgow and Wales.Previously, Professor McVie was Chief Executive of the Cancer Research Campaign (CRC), which, under his aegis, took over 60 molecules from the lab into clinical trial. He led CRC into a merger with Imperial Cancer Research Fund, which formed Cancer Research UK in 2002, and was joint CEO with Sir Paul Nurse.

François Meyer

Dr François Meyer is currently Advisor to the President of the French National Authority for Health (HAS), with a particular focus on international affairs. He joined HAS in 2005 with the responsibility of setting up the Health Technology Assessment Division.Prior to joining HAS, Dr Meyer worked for five years at the French Health Products Agency, initially as Deputy Director of the Regulatory Division and then as Director of the Drugs and Devices HTA Division. Before this position, he worked for five years in the R&D division of a pharmaceutical company.

Jean Mossman

Jean Mossman is an independent healthcare consultant. She works with patient organisations and pharmaceutical companies, with the focus of putting the patient at the heart of healthcare delivery. Jean volunteers as the Policy Lead for the European Brain Council.

As former Chief Executive at CancerBACUP, a cancer information charity, Jean set up its first cancer information drop-in centres in hospitals. She also played a central role in organising clinical research programmes in the UK as Executive Secretary of the UK Coordinating Committee on Cancer Research.

Together with Mary Baker and the London School of Economics and Political Science, Jean developed and delivered training courses for patient groups on health technology assessment.

Huseyin Naci

Huseyin Naci is an Assistant Professor of Health Policy at LSE. Dr Naci's academic interests include comparative effectiveness research, drug regulation, and health policy evaluation. His current projects are focused on the unintended consequences of health policies; market entry requirements for new health technologies; and economic access to medications. Prior to joining LSE, Dr Naci was a Thomas O. Pyle Fellow in Population Medicine at Harvard University and a Fellow in Pharmaceutical Policy Research at Harvard Medical School and Harvard Pilgrim Health Care Institute in Boston, USA.

Elena Nicod   LSE Summit Scientific Committee

Elena Nicod is a Research Officer at LSE Health. Her areas of interest include pharmaceutical policy and economics, and specifically pricing and reimbursement, access to medicines, Health Technology Assessment (HTA), rare diseases and orphan drugs, and patient involvement in HTA. Her main research focuses on better understanding the application of HTA in different settings within the areas of rare diseases, cancer and central nervous system treatments. Other research projects investigate the burden of illness of a retinal disorder, and the costing of a retinal surgical procedure in the UK. She also participates in a number of EU-funded projects (Advance-HTA, Burqol, Rare-BP).

Prior to LSE, Elena worked as Coordinator of a clinical trial unit at the University Hospital (CHUV) in Lausanne, and as Administrator of the Swiss Vaccine Research Institute during its launch in 2009. Elena is undertaking a PhD in Social Policy at LSE, holds an MSc HPPF from the London School of Hygiene & Tropical Medicine, and a BSc/MSc in Business Administration from HEC Lausanne, Switzerland.

Andrea Rappagliosi

Andrea Rappagliosi is President of Vaccines Europe, the European Vaccine Manufacturers Association, and  Vice President Market Access, Health Policy and Medical Affairs at Sanofi Pasteur MSD.

He began his career in the Italian Government and then the Senate, focusing on drafting of legislative texts, comparative legal studies and public budget analysis.

In 1992, he moved into healthcare and worked for The Ares-Serono Group as Head of the Institutional Affairs Department in charge of the Rome and Brussels offices. From 1995 to 1999, he was Public Affairs Director at Baxter Healthcare, part of the European Public Affairs team before returning to Serono International, today Merck Serono, as Vice President Health Policy & Market Access.  In April 2009, Andrea joined GlaxoSmithKline as Vice President European Government Affairs & Head of Brussels Office.

Andrea is Co-Chair of the HTA Task Force of EFPIA, the European Association of the R&D pharmaceutical Industry; Industry representative at the EU HTA Network; Past President of EuropaBio and member of its Board; a member of the European Commission High Level Pharmaceutical Forum  representing the Biotechnology Industry; Industry representative at the EMEA/COMP (European Medicines Evaluation Agency/Committee for Orphan Medicinal Products) Working Group with Interested Parties; and member of the British Institute of International and Comparative Law.

 Michael Rawlins

Professor Sir Michael Rawlins MD FRCP FMedSci is chairman of the Medicines and Healthcare products Regulatory Agency (since December 2014). He is a clinical pharmacologist and specialist in internal medicine. He was professor of clinical pharmacology in Newcastle, and physician at the Newcastle Hospitals, from 1999-2006.

He was chairman of the Committee on Safety of Medicines (1992-1998), chairman of the Advisory Council on the Misuse of Drugs (1998-2008) and founding chairman of the National Institute for Clinical Excellence (1999-2013). He is recent past president of the Royal Society of Medicine (2012-2014).

Currently Sir Michael is chairman of UK Biobank, honorary professor at the London School of Hygiene and Tropical Medicine, and emeritus professor at the University of Newcastle upon Tyne.

Ri de Ridder

Henri De Ridder has been Director-General of the Health Insurance Department at the National Institute for Health and Disability Insurance, Brussels, Belgium since 2005. He graduated from the University of Ghent as a doctor of medicine, surgery and obstetrics in 1976. He was general practitioner in a primary health centre from 1976 till 2000. He was counselor and deputy director in the cabinet of Ministers of Health and of Social Affairs from 1997 till 2005. He has considerable experience in public health policy, public administration, primary health care, social equity and equal access, chronic care and health insurance.

Bettina Ryll

Bettina Ryll, MD, PhD studied Medicine in Germany (Freie Universität Berlin) and France (Paris V and VI) and obtained a PhD in Biomedical Sciences from University College London.

After losing her husband to melanoma, she founded the Melanoma Patient Network Europe in 2013 and developed a special interest in patient-centric clinical research and drug development. Bettina’s current areas of focus are Adaptive Licensing/ MAPPS, innovative sustainable healthcare models and  patient-centered risk/ benefit assessment tools.

Bettina lectures and advises on patient-centric drug development; she is a member of ASCO and ISPOR and currently holds the Chair of the ESMO Patient Advocacy Working Group. 

Claudine Sapède

Dr Claudine Sapède is Global HTA and Payment Policy Lead at Roche, based in Basel. In her role Claudine works on the development of Roche’s external policy positions and projects on a number of market access subjects including HTA and pricing. Prior to this role Claudine held the position of Director of economic affairs, pricing and market access at Roche in France. She has been working in the pharmaceutical sector in the field of reimbursement, market access and pricing for more than 20 years, both at national and international levels.

Claudine trained as a pharmacist at University of Clermont-Ferrand and holds an MSc in health economics and applied mathematics (Lyon University).

Jack Scannell

Dr Jack Scannell researches biomedical R&D productivity from both a financial and scientific perspective, particularly the contrast between cheaper and better scientific inputs, and what has been a long-term decline in output efficiency. He works as an independent consultant to drug and biotechnology companies, financial institutions, and public sector bodies. He is an Associate Fellow at the Centre for the Advancement of Sustainable Innovation (CASMI) at Oxford University, an Associate Member of the Innogen Institute, and an Honorary Fellow at Edinburgh University.

Jack was formerly Head of Discovery Research at e-Therapeutics PLC, an Oxford-based biotechnology firm, applying bio-informatics methods to drug discovery. Prior to that, hwe worked in drug industry investment, leading the European Healthcare team at Sanford Bernstein from 2005 and 2012. From 1999 to 2005, Jack worked at the Boston Consulting Group with healthcare and financial clients. He has a PhD in Physiology (Computational Neuroscience) from Oxford University and a degree in Medical Sciences from Cambridge University.

David Taylor

David Taylor has been involved in pharmaceutical and public health policy at the UCL School of Pharmacy since 2001. During this time he has also been Chair of Camden and Islington NHS Foundation Trust and a Non-Executive Director of the Camden Primary Care Trust.

He has published extensively on issues related to health. As Associate Director of Health Studies at the Audit Commission for England and Wales, he wrote the national study ‘Dear to our hearts’, accompanied by the national audit. These were forerunners of the National Service Framework on coronary heart disease. David’s current work includes studies on public health and pharmaceutical policy formation and the future global development of pharmacy, the pharmaceutical industry and health care provision.

Anna Zawada

Anna Zawada, MSc, is Director of the Office of Transparency and Tariff Councils, Agency for Health Technology Assessment and Tariff System (AOTMiT), Warsaw, Poland.

She graduated from Warsaw University. While cooperating with Agency’s Councils, she leads the Division of Analytical Support and International Cooperation in AOTMiT. She is the AOTMiT representative at the ISPOR Europe HTA Roundtable. As the representative of AOTMiT she took part in EUnetHTA Joint Action 2 and Advance-HTA EC co-funded projects. She is skilled in HTA analysis performance and assessment, and experienced in health policy interpretation and implementation, as well as in consultancy on operational law description. She is an HTA educator (Warsaw University of Technology Business School); HTA researcher (Warsaw Medical University, field of interest: assessment of inequities in health care); a member of ISPOR Polish Chapter and co-editor of the Polish editions of ISPOR publications: ISPOR Book of Terms and Therapeutic & Diagnostic Device Outcomes Research.